Fig. 4

CS treatment improves memory-relevant behavior and levels of synaptic proteins in male E3FAD. Acquisition (A) and probe (B and C) trials in the Morris water maze test. In the acquisition phase, there was an effect of the day but not treatment in all groups. B and C Probe/memory trial performance. CS treatment in male E3FAD mice resulted in a lower latency to platform (p = 0.0064) (B) and a higher number of platform crosses (p = 0.0170) (C). CS treatment in female E3FADs resulted in higher latency to platform (p = 0.03666) (B) and lower number of platform crosses (p = 0.0020) (C). D–F Synaptic protein levels quantified by western blot. In male E3FAD mice, CS treatment resulted in higher levels of D GAD67 (p = 0.0408), E PSD95 (p = 0.0326), and, although non-significant, F drebrin levels (p = 0.066). Data are expressed as mean ± SEM for behavior (n = 8–10) and western blot (n = 5–12). MWM acquisition data were analyzed by 2-way ANOVA for treatment and day of test, followed by Tukey’s post hoc. Probe and western blot data were analyzed by by t-test, *: p < 0.05 CS vs. VC. Synaptic proteins were measured in the cortex. All data is from the same cohort of mice; the n’s differ because of study design, technical issues, and outlier tests